Anthony P. Zook - 01 Jun 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role: Chief Executive Officer, Director
Signature: /s/ Ali Olivo, Attorney-in-Fact
Issuer symbol: NEO
Transactions as of: 01 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:06:43 UTC
Previous filing: 08 May 2025
Next filing: 06 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Zook Anthony P.	Chief Executive Officer, Director	9490 NEOGENOMICS WAY, FORT MYERS	/s/ Ali Olivo, Attorney-in-Fact	03 Jun 2025	0001582393

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NEO	Common Stock	Options Exercise	$0	+12,254	+108%	$0.000000	23,590	01 Jun 2025	Direct	F1
transaction	NEO	Common Stock	Tax liability	$0	-3,424	-15%	$0.000000	20,166	01 Jun 2025	Direct	F2
holding	NEO	Common Stock						18,900	01 Jun 2025	Amended and Restated Anthony P. Zook Living Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NEO	Restricted Stock Unit	Options Exercise	$0	-12,254	-100%	$0.000000	0	01 Jun 2025	Common Stock	12,254	$0.000000	Direct	F3
holding	NEO	Stock Option (Right to Buy)						8,353	01 Jun 2025	Common Stock	8,353	$14.82	Direct
holding	NEO	Stock Option (Right to Buy)						8,672	01 Jun 2025	Common Stock	8,672	$13.71	Direct
holding	NEO	Stock Option (Right to Buy)						729,927	01 Jun 2025	Common Stock	729,927	$10.44	Direct	F4, F5
holding	NEO	Restricted Stock Unit						421,496	01 Jun 2025	Common Stock	421,496	$0.000000	Direct	F3, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects release of restricted stock units that were previously reported on a Form 4.
F2	Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2024 vesting of restricted stock.
F3	Once vested, the shares of common stock are not subject to expiration.
F4	This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F5	On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F6	On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.